Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 423

1.

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.

Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE.

Vaccine. 2000 Oct 15;19(4-5):483-91.

PMID:
11027812
2.

Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.

Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):343-9.

PMID:
10466959
3.

Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.

Konishi E, Kurane I, Mason PW, Shope RE, Ennis FA.

Virology. 1997 Jan 20;227(2):353-60.

4.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

PMID:
14551893
5.

Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.

Tartaglia J, Cox WI, Pincus S, Paoletti E.

Dev Biol Stand. 1994;82:125-9. Review.

PMID:
7958466
6.

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates.

Konishi E, Kurane I, Mason PW, Shope RE, Kanesa-Thasan N, Smucny JJ, Hoke CH Jr, Ennis FA.

Vaccine. 1998 May;16(8):842-9. Erratum in: Vaccine 1999 Feb 5;17(5):I.

PMID:
9627942
7.
8.

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F.

Vaccine. 1999 Apr 9;17(15-16):1869-82.

PMID:
10217584
9.

Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein.

Jan LR, Yang CS, Henchal LS, Sumiyoshi H, Summers PL, Dubois DR, Lai CJ.

Am J Trop Med Hyg. 1993 Mar;48(3):412-23.

PMID:
8385887
10.

Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus.

Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K.

J Virol. 1990 Jun;64(6):2788-95.

11.

Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.

Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J.

Dev Biol Stand. 1995;84:159-63. Review.

PMID:
7796949
12.
13.

IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.

Appaiahgari MB, Vrati S.

Expert Rev Vaccines. 2010 Dec;9(12):1371-84. doi: 10.1586/erv.10.139. Review.

PMID:
21105774
14.
15.

Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines.

Chen HW, Pan CH, Liau MY, Jou R, Tsai CJ, Wu HJ, Lin YL, Tao MH.

J Virol. 1999 Dec;73(12):10137-45.

16.

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR, et al.

J Infect Dis. 1998 Jun;177(6):1664-73.

PMID:
9607847
17.
18.

Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.

Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K.

Vaccine. 2009 Apr 6;27(16):2258-64. doi: 10.1016/j.vaccine.2009.02.006. Epub 2009 Feb 12.

PMID:
19428840
20.

Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice.

Li Y, Ye J, Cao S, Xiao S, Zhao Q, Liu X, Jin M, Chen H.

J Gene Med. 2009 Feb;11(2):150-9. doi: 10.1002/jgm.1282. Retraction in: J Gene Med. 2009 May;11(5):454.

PMID:
19040206

Supplemental Content

Support Center